Susceptibility of HIV-1 non-B subtypes and recombinant variants to Enfuvirtide
Data on susceptibility of HIV-1 non-B subtypes to Enfuvirtide (ENF) is rather limited. To determine if ENF could be active in vitro against HIV-1 non-B subtypes and how the gp41 genetic variability across variants may influence ENF susceptibility. Using PHENOSCRIPT ® Env, a recombinant envelope viru...
Saved in:
Published in | Journal of clinical virology Vol. 38; no. 2; pp. 176 - 180 |
---|---|
Main Authors | , , , |
Format | Journal Article |
Language | English |
Published |
Amsterdam
Elsevier B.V
01.02.2007
Elsevier Science |
Subjects | |
Online Access | Get full text |
ISSN | 1386-6532 1873-5967 |
DOI | 10.1016/j.jcv.2006.09.002 |
Cover
Abstract | Data on susceptibility of HIV-1 non-B subtypes to Enfuvirtide (ENF) is rather limited.
To determine if ENF could be active
in vitro against HIV-1 non-B subtypes and how the gp41 genetic variability across variants may influence ENF susceptibility.
Using PHENOSCRIPT
® Env, a recombinant envelope virus assay, ENF susceptibility was investigated in isolates from 19 drug-naive HIV-1-infected individuals harboring non-B subtypes.
Using phylogenetic analyses of the gp41 gene, distinct HIV-1 subtypes were recognized: A (2), C (5), D (1), F (2), G (1), J (1), CRF02_AG (6) and CRF06 (1). Susceptibility to ENF and IC
50 values
in vitro could be obtained in only 13 (68.4%) specimens, most likely due to the high genetic variability in HR1 and HR2 regions in the remaining cases. A wide range of IC
50 values with a median of 0.013
μg/ml was observed (range, 0.005–0.180
μg/ml). Natural polymorphisms, but not classical ENF resistance associated mutations within HR1 (residues 36–45) were identified in most non-B viruses.
This study provides information about the baseline susceptibility to ENF in antiretroviral-naive subjects infected with different HIV-1 non-B subtypes. Susceptibility to ENF seems to be preserved despite high genetic variability in HR1 and HR2 regions. |
---|---|
AbstractList | Data on susceptibility of HIV-1 non-B subtypes to Enfuvirtide (ENF) is rather limited.
To determine if ENF could be active
in vitro against HIV-1 non-B subtypes and how the gp41 genetic variability across variants may influence ENF susceptibility.
Using PHENOSCRIPT
® Env, a recombinant envelope virus assay, ENF susceptibility was investigated in isolates from 19 drug-naive HIV-1-infected individuals harboring non-B subtypes.
Using phylogenetic analyses of the gp41 gene, distinct HIV-1 subtypes were recognized: A (2), C (5), D (1), F (2), G (1), J (1), CRF02_AG (6) and CRF06 (1). Susceptibility to ENF and IC
50 values
in vitro could be obtained in only 13 (68.4%) specimens, most likely due to the high genetic variability in HR1 and HR2 regions in the remaining cases. A wide range of IC
50 values with a median of 0.013
μg/ml was observed (range, 0.005–0.180
μg/ml). Natural polymorphisms, but not classical ENF resistance associated mutations within HR1 (residues 36–45) were identified in most non-B viruses.
This study provides information about the baseline susceptibility to ENF in antiretroviral-naive subjects infected with different HIV-1 non-B subtypes. Susceptibility to ENF seems to be preserved despite high genetic variability in HR1 and HR2 regions. Data on susceptibility of HIV-1 non-B subtypes to Enfuvirtide (ENF) is rather limited.BACKGROUNDData on susceptibility of HIV-1 non-B subtypes to Enfuvirtide (ENF) is rather limited.To determine if ENF could be active in vitro against HIV-1 non-B subtypes and how the gp41 genetic variability across variants may influence ENF susceptibility.OBJECTIVETo determine if ENF could be active in vitro against HIV-1 non-B subtypes and how the gp41 genetic variability across variants may influence ENF susceptibility.Using PHENOSCRIPT Env, a recombinant envelope virus assay, ENF susceptibility was investigated in isolates from 19 drug-naive HIV-1-infected individuals harboring non-B subtypes.METHODSUsing PHENOSCRIPT Env, a recombinant envelope virus assay, ENF susceptibility was investigated in isolates from 19 drug-naive HIV-1-infected individuals harboring non-B subtypes.Using phylogenetic analyses of the gp41 gene, distinct HIV-1 subtypes were recognized: A (2), C (5), D (1), F (2), G (1), J (1), CRF02_AG (6) and CRF06 (1). Susceptibility to ENF and IC(50) values in vitro could be obtained in only 13 (68.4%) specimens, most likely due to the high genetic variability in HR1 and HR2 regions in the remaining cases. A wide range of IC(50) values with a median of 0.013 microg/ml was observed (range, 0.005-0.180 microg/ml). Natural polymorphisms, but not classical ENF resistance associated mutations within HR1 (residues 36-45) were identified in most non-B viruses.RESULTSUsing phylogenetic analyses of the gp41 gene, distinct HIV-1 subtypes were recognized: A (2), C (5), D (1), F (2), G (1), J (1), CRF02_AG (6) and CRF06 (1). Susceptibility to ENF and IC(50) values in vitro could be obtained in only 13 (68.4%) specimens, most likely due to the high genetic variability in HR1 and HR2 regions in the remaining cases. A wide range of IC(50) values with a median of 0.013 microg/ml was observed (range, 0.005-0.180 microg/ml). Natural polymorphisms, but not classical ENF resistance associated mutations within HR1 (residues 36-45) were identified in most non-B viruses.This study provides information about the baseline susceptibility to ENF in antiretroviral-naive subjects infected with different HIV-1 non-B subtypes. Susceptibility to ENF seems to be preserved despite high genetic variability in HR1 and HR2 regions.CONCLUSIONThis study provides information about the baseline susceptibility to ENF in antiretroviral-naive subjects infected with different HIV-1 non-B subtypes. Susceptibility to ENF seems to be preserved despite high genetic variability in HR1 and HR2 regions. Data on susceptibility of HIV-1 non-B subtypes to Enfuvirtide (ENF) is rather limited. To determine if ENF could be active in vitro against HIV-1 non-B subtypes and how the gp41 genetic variability across variants may influence ENF susceptibility. Using PHENOSCRIPT Env, a recombinant envelope virus assay, ENF susceptibility was investigated in isolates from 19 drug-naive HIV-1-infected individuals harboring non-B subtypes. Using phylogenetic analyses of the gp41 gene, distinct HIV-1 subtypes were recognized: A (2), C (5), D (1), F (2), G (1), J (1), CRF02_AG (6) and CRF06 (1). Susceptibility to ENF and IC(50) values in vitro could be obtained in only 13 (68.4%) specimens, most likely due to the high genetic variability in HR1 and HR2 regions in the remaining cases. A wide range of IC(50) values with a median of 0.013 microg/ml was observed (range, 0.005-0.180 microg/ml). Natural polymorphisms, but not classical ENF resistance associated mutations within HR1 (residues 36-45) were identified in most non-B viruses. This study provides information about the baseline susceptibility to ENF in antiretroviral-naive subjects infected with different HIV-1 non-B subtypes. Susceptibility to ENF seems to be preserved despite high genetic variability in HR1 and HR2 regions. Abstract Background Data on susceptibility of HIV-1 non-B subtypes to Enfuvirtide (ENF) is rather limited. Objective To determine if ENF could be active in vitro against HIV-1 non-B subtypes and how the gp41 genetic variability across variants may influence ENF susceptibility. Methods Using PHENOSCRIPT® Env, a recombinant envelope virus assay, ENF susceptibility was investigated in isolates from 19 drug-naive HIV-1-infected individuals harboring non-B subtypes. Results Using phylogenetic analyses of the gp41 gene, distinct HIV-1 subtypes were recognized: A (2), C (5), D (1), F (2), G (1), J (1), CRF02_AG (6) and CRF06 (1). Susceptibility to ENF and IC50 values in vitro could be obtained in only 13 (68.4%) specimens, most likely due to the high genetic variability in HR1 and HR2 regions in the remaining cases. A wide range of IC50 values with a median of 0.013 μg/ml was observed (range, 0.005–0.180 μg/ml). Natural polymorphisms, but not classical ENF resistance associated mutations within HR1 (residues 36–45) were identified in most non-B viruses. Conclusion This study provides information about the baseline susceptibility to ENF in antiretroviral-naive subjects infected with different HIV-1 non-B subtypes. Susceptibility to ENF seems to be preserved despite high genetic variability in HR1 and HR2 regions. Background: Data on susceptibility of HIV-1 non-B subtypes to Enfuvirtide (ENF) is rather limited. Objective: To determine if ENF could be active in vitro against HIV-1 non-B subtypes and how the gp41 genetic variability across variants may influence ENF susceptibility. Methods: Using PHENOSCRIPT super(()R) Env, a recombinant envelope virus assay, ENF susceptibility was investigated in isolates from 19 drug-naive HIV-1-infected individuals harboring non-B subtypes. Results: Using phylogenetic analyses of the gp41 gene, distinct HIV-1 subtypes were recognized: A (2), C (5), D (1), F (2), G (1), J (1), CRF02_AG (6) and CRF06 (1). Susceptibility to ENF and IC sub(5) sub(0) values in vitro could be obtained in only 13 (68.4%) specimens, most likely due to the high genetic variability in HR1 and HR2 regions in the remaining cases. A wide range of IC sub(5) sub(0) values with a median of 0.013 mu g/ml was observed (range, 0.005-0.180 mu g/ml). Natural polymorphisms, but not classical ENF resistance associated mutations within HR1 (residues 36-45) were identified in most non-B viruses. Conclusion: This study provides information about the baseline susceptibility to ENF in antiretroviral-naive subjects infected with different HIV-1 non-B subtypes. Susceptibility to ENF seems to be preserved despite high genetic variability in HR1 and HR2 regions. |
Author | Labernardière, Jean-Louis Holguín, Africa Soriano, Vincent Faudon, Jean Louis |
Author_xml | – sequence: 1 givenname: Africa surname: Holguín fullname: Holguín, Africa email: aholguin.hciii@salud.madrid.org organization: Service of Infectious Diseases, Hospital Carlos III, Madrid, Spain – sequence: 2 givenname: Jean Louis surname: Faudon fullname: Faudon, Jean Louis organization: Eurofins Viralliance, Paris, France – sequence: 3 givenname: Jean-Louis surname: Labernardière fullname: Labernardière, Jean-Louis organization: Eurofins Viralliance, Paris, France – sequence: 4 givenname: Vincent surname: Soriano fullname: Soriano, Vincent organization: Service of Infectious Diseases, Hospital Carlos III, Madrid, Spain |
BackLink | http://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=18474447$$DView record in Pascal Francis https://www.ncbi.nlm.nih.gov/pubmed/17196877$$D View this record in MEDLINE/PubMed |
BookMark | eNqFkk2L1TAUhoOMOB_6A9xIN7prPWnTfCAIOozOwKCLUbchTVJI7U2uSXrh_ntT7lVhwJlNTgjP-x7OeXOOTnzwFqGXGBoMmL6dmknvmhaANiAagPYJOsOcdXUvKDsp947TmvZde4rOU5oAcN8R9gydYoYF5YydoS93S9J2m93gZpf3VRir65sfNa5Kq_pjlZYh77c2VcqbKlodNoPzyudqp6IrNVU5VFd-XHYuZmfsc_R0VHOyL471An3_dPXt8rq-_fr55vLDba17zHLNO9WrTvQt74BbAoOiuiVq5JgRa3DPmDCqoEB1eRKAR8JHrDkxylhjoLtAbw6-2xh-LTZluXFljnlW3oYlScpFC4TxR8EWWtqRfnV8dQSXYWON3Ea3UXEv_6yqAK-PgEpazWNUXrv0j-OEEUJWjh04HUNK0Y5Su6yyCz5H5WaJQa7hyUmW8OQangQhS3hFie8p_5o_oHl30Niy7Z2zUSbtrNfWuBJXlia4B9Xv76n17Lwr4_20e5umsERfYpRYplaCvFs_1PqfgAKUUxQD8X-DR5r_BmH71_0 |
CitedBy_id | crossref_primary_10_1517_14656566_9_13_2349 crossref_primary_10_1517_14656566_2010_522178 crossref_primary_10_3390_v5020595 crossref_primary_10_1089_aid_2009_0151 crossref_primary_10_1089_aid_2008_0134 crossref_primary_10_2217_17469600_2_6_579 crossref_primary_10_2217_17469600_1_3_273 crossref_primary_10_1089_aid_2007_0130 crossref_primary_10_1089_aid_2008_0219 crossref_primary_10_1016_j_jcv_2009_05_001 crossref_primary_10_1057_biosoc_2010_37 crossref_primary_10_1097_QAD_0000000000001796 crossref_primary_10_1089_aid_2009_0014 crossref_primary_10_1586_14787210_2013_844649 crossref_primary_10_1089_aid_2006_0256 crossref_primary_10_3390_v3040347 crossref_primary_10_3390_v4123859 |
Cites_doi | 10.1089/aid.2006.22.357 10.1128/JCM.38.4.1370-1374.2000 10.1089/088922204323087714 10.1128/JCM.28.3.495-503.1990 10.1128/JVI.77.2.1610-1613.2003 10.1128/JVI.79.2.764-770.2005 10.1089/aid.2005.21.430 10.1146/annurev.biochem.70.1.777 10.1097/01.qai.0000174656.71276.d6 10.1089/0889222041725271 10.1097/00002030-200409030-00007 10.1371/journal.pmed.0020112 10.1097/01.aids.0000180785.25800.de 10.1089/aid.2005.21.583 10.1097/01.aids.0000188425.79914.e4 10.1128/JVI.78.14.7582-7589.2004 10.1097/00126334-200306010-00003 10.1128/AAC.49.3.1113-1119.2005 10.1128/JCM.40.11.4313-4316.2002 |
ContentType | Journal Article |
Copyright | 2006 2007 INIST-CNRS |
Copyright_xml | – notice: 2006 – notice: 2007 INIST-CNRS |
DBID | AAYXX CITATION IQODW CGR CUY CVF ECM EIF NPM 7U9 H94 7X8 |
DOI | 10.1016/j.jcv.2006.09.002 |
DatabaseName | CrossRef Pascal-Francis Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed Virology and AIDS Abstracts AIDS and Cancer Research Abstracts MEDLINE - Academic |
DatabaseTitle | CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) AIDS and Cancer Research Abstracts Virology and AIDS Abstracts MEDLINE - Academic |
DatabaseTitleList | MEDLINE - Academic MEDLINE AIDS and Cancer Research Abstracts |
Database_xml | – sequence: 1 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database |
DeliveryMethod | fulltext_linktorsrc |
Discipline | Biology |
EISSN | 1873-5967 |
EndPage | 180 |
ExternalDocumentID | 17196877 18474447 10_1016_j_jcv_2006_09_002 S1386653206003209 1_s2_0_S1386653206003209 |
Genre | Research Support, Non-U.S. Gov't Journal Article |
GroupedDBID | --- --K --M .1- .FO .GJ .~1 0R~ 1B1 1P~ 1RT 1~. 1~5 29K 4.4 457 4CK 4G. 53G 5GY 5VS 7-5 71M 8P~ AAAJQ AABNK AAEDT AAEDW AAIKJ AAKOC AALRI AAOAW AAQFI AAQXK AARKO AATTM AAXKI AAXUO AAYWO ABBQC ABFNM ABFRF ABJNI ABMAC ABMZM ABWVN ABXDB ACDAQ ACGFO ACGFS ACIEU ACIUM ACRLP ACRPL ACVFH ADBBV ADCNI ADEZE ADMUD ADNMO ADVLN AEBSH AEFWE AEIPS AEKER AENEX AEUPX AEVXI AFJKZ AFPUW AFRHN AFTJW AFXIZ AGCQF AGEKW AGHFR AGQPQ AGUBO AGYEJ AIEXJ AIGII AIIUN AIKHN AITUG AJRQY AJUYK AKBMS AKRWK AKYEP ALMA_UNASSIGNED_HOLDINGS AMRAJ ANKPU ANZVX APXCP ASPBG AVWKF AXJTR AZFZN BKOJK BLXMC BNPGV CJTIS CS3 D-I DU5 EBS EFJIC EFKBS EJD EO8 EO9 EP2 EP3 F5P FDB FEDTE FGOYB FIRID FNPLU FYGXN G-Q GBLVA HVGLF HX~ HZ~ IHE J1W KOM LUGTX M41 MO0 N9A O-L O9- OAUVE OD- OO. OZT P-8 P-9 P2P PC. Q38 R2- ROL RPZ SCC SDF SDG SDP SEL SES SEW SPCBC SSH SSI SSZ T5K UNMZH Z5R ~G- AACTN AFCTW AFKWA AJOXV AMFUW RIG AAIAV ABLVK ABYKQ AJBFU EFLBG LCYCR AAYXX AGRNS CITATION IQODW CGR CUY CVF ECM EIF NPM 7U9 H94 7X8 |
ID | FETCH-LOGICAL-c517t-83a5a39528308e40ba6c24af8174ed15779dac5106c817901f48f1c84dadedd03 |
IEDL.DBID | .~1 |
ISSN | 1386-6532 |
IngestDate | Fri Sep 05 09:26:54 EDT 2025 Fri Sep 05 13:50:45 EDT 2025 Wed Feb 19 01:46:36 EST 2025 Mon Jul 21 09:16:53 EDT 2025 Tue Jul 01 02:51:33 EDT 2025 Thu Apr 24 22:53:06 EDT 2025 Fri Feb 23 02:25:04 EST 2024 Sun Feb 23 10:19:39 EST 2025 Tue Aug 26 19:31:36 EDT 2025 |
IsPeerReviewed | true |
IsScholarly | true |
Issue | 2 |
Keywords | HIV-1 Subtypes Enfuvirtide Drug resistance Gp41 Microbiology HIV-1 virus Retroviridae Lentivirus Virology Virus Resistance Sensitivity Human immunodeficiency virus Subtype |
Language | English |
License | https://www.elsevier.com/tdm/userlicense/1.0 CC BY 4.0 |
LinkModel | DirectLink |
MergedId | FETCHMERGED-LOGICAL-c517t-83a5a39528308e40ba6c24af8174ed15779dac5106c817901f48f1c84dadedd03 |
Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 |
PMID | 17196877 |
PQID | 20263450 |
PQPubID | 23462 |
PageCount | 5 |
ParticipantIDs | proquest_miscellaneous_68920478 proquest_miscellaneous_20263450 pubmed_primary_17196877 pascalfrancis_primary_18474447 crossref_citationtrail_10_1016_j_jcv_2006_09_002 crossref_primary_10_1016_j_jcv_2006_09_002 elsevier_sciencedirect_doi_10_1016_j_jcv_2006_09_002 elsevier_clinicalkeyesjournals_1_s2_0_S1386653206003209 elsevier_clinicalkey_doi_10_1016_j_jcv_2006_09_002 |
ProviderPackageCode | CITATION AAYXX |
PublicationCentury | 2000 |
PublicationDate | 2007-02-01 |
PublicationDateYYYYMMDD | 2007-02-01 |
PublicationDate_xml | – month: 02 year: 2007 text: 2007-02-01 day: 01 |
PublicationDecade | 2000 |
PublicationPlace | Amsterdam |
PublicationPlace_xml | – name: Amsterdam – name: Netherlands |
PublicationTitle | Journal of clinical virology |
PublicationTitleAlternate | J Clin Virol |
PublicationYear | 2007 |
Publisher | Elsevier B.V Elsevier Science |
Publisher_xml | – name: Elsevier B.V – name: Elsevier Science |
References | Boom, Sol, Salimans, Jansen, Wertheim-van Dillen, van der Noordaa (bib2) 1990; 28 Stanfield-Oakley, Mosier, Davison (bib23) 2005; 10 Mink, Greenberg, Mosier, Janumpalli, Davison, Jin (bib14) 2002; 7 Cilliers, Patient, Pillay, Papathanasopoulos, Morris (bib5) 2004; 20 Fleury, Toni, Lan (bib8) 2006; 22 Poveda, Briz, Soriano (bib18) 2005; 7 Kantor, Katzenstein, Efron (bib12) 2005; 2 Chinnadurai, Munch, Dittmar, Kirchhoff (bib3) 2005; 19 Aghokeng, Ewane, Awazi (bib1) 2005; 21 Rodés, Poveda, Soriano (bib20) 2002; 41 Poveda, Barreiro, Rodes, Soriano (bib17) 2005; 21 Nakemi, Kodama, Ikeuchi (bib15) 2005; 79 Sista, Melby, Davison (bib22) 2004; 18 Xu, Pozniak, Wildfire (bib24) 2005; 49 Labrosse, Labernardiere, Dam (bib13) 2003; 7 Nicastri, Sarmati, d’Éttorre (bib16) 2004; 20 Frater (bib9) 2002; 7 Eckert, Kim (bib6) 2001; 70 Heil, Decker, Sfakianos, Shaw, Hunter, Derdeyn (bib10) 2004; 78 Eshleman, Guay, Wang (bib7) 2005; 40 Rodés, Holguín, Soriano (bib19) 2000; 38 Roman, Gonzalez, Lambert (bib21) 2003; 33 Chinnadurai, Munch, Kirchhoff (bib4) 2005; 19 Holguin, Ramírez de Arellano, Rivas, Soriano (bib11) 2006; 8 Eckert (10.1016/j.jcv.2006.09.002_bib6) 2001; 70 Rodés (10.1016/j.jcv.2006.09.002_bib20) 2002; 41 Nakemi (10.1016/j.jcv.2006.09.002_bib15) 2005; 79 Labrosse (10.1016/j.jcv.2006.09.002_bib13) 2003; 7 Mink (10.1016/j.jcv.2006.09.002_bib14) 2002; 7 Sista (10.1016/j.jcv.2006.09.002_bib22) 2004; 18 Nicastri (10.1016/j.jcv.2006.09.002_bib16) 2004; 20 Frater (10.1016/j.jcv.2006.09.002_bib9) 2002; 7 Poveda (10.1016/j.jcv.2006.09.002_bib17) 2005; 21 Chinnadurai (10.1016/j.jcv.2006.09.002_bib4) 2005; 19 Fleury (10.1016/j.jcv.2006.09.002_bib8) 2006; 22 Rodés (10.1016/j.jcv.2006.09.002_bib19) 2000; 38 Aghokeng (10.1016/j.jcv.2006.09.002_bib1) 2005; 21 Boom (10.1016/j.jcv.2006.09.002_bib2) 1990; 28 Eshleman (10.1016/j.jcv.2006.09.002_bib7) 2005; 40 Xu (10.1016/j.jcv.2006.09.002_bib24) 2005; 49 Chinnadurai (10.1016/j.jcv.2006.09.002_bib3) 2005; 19 Holguin (10.1016/j.jcv.2006.09.002_bib11) 2006; 8 Cilliers (10.1016/j.jcv.2006.09.002_bib5) 2004; 20 Poveda (10.1016/j.jcv.2006.09.002_bib18) 2005; 7 Kantor (10.1016/j.jcv.2006.09.002_bib12) 2005; 2 Roman (10.1016/j.jcv.2006.09.002_bib21) 2003; 33 Stanfield-Oakley (10.1016/j.jcv.2006.09.002_bib23) 2005; 10 Heil (10.1016/j.jcv.2006.09.002_bib10) 2004; 78 |
References_xml | – volume: 7 start-page: 139 year: 2005 end-page: 147 ident: bib18 article-title: Enfuvirtide, the first fusion inhibitor to treat HIV infection publication-title: AIDS Rev – volume: 70 start-page: 777 year: 2001 end-page: 810 ident: bib6 article-title: Mechanisms of viral membrane fusion and its inhibition publication-title: Annu Rev Biochem – volume: 28 start-page: 495 year: 1990 end-page: 503 ident: bib2 article-title: Rapid and simple method for purification of nucleic acids publication-title: J Clin Microbiol – volume: 79 start-page: 764 year: 2005 end-page: 770 ident: bib15 article-title: Mutations conferring resistance to HIV-1 fusion inhibitors are restricted by gp41 and rev-responsive element functions publication-title: J Virol – volume: 78 start-page: 7582 year: 2004 end-page: 7589 ident: bib10 article-title: Determinants of HIV-1 baseline susceptibility to the fusion inhibitors Enfuvirtide and T-649 reside outside the peptide interaction site publication-title: J Virol – volume: 19 start-page: 1401 year: 2005 end-page: 1405 ident: bib4 article-title: Effect of naturally-occurring gp41 HR1 variations on susceptibility of HIV-1 to fusion inhibitors publication-title: AIDS – volume: 40 start-page: 24 year: 2005 end-page: 29 ident: bib7 article-title: Distinct patterns of emergence and fading of K103N and Y181C in women with subtype A vs. D after single-dose nevirapine: HIVNET 012 publication-title: J Acquir Immune Defic Syndr – volume: 2 start-page: 325 year: 2005 end-page: 337 ident: bib12 article-title: Impact of HIV-1 subtype and antiretroviral therapy on protease and reverse transcriptase genotype: results of a global collaboration publication-title: PLoS Med – volume: 20 start-page: 477 year: 2004 end-page: 482 ident: bib5 article-title: Sensitivity of HIV-1 subtype C isolates to entry inhibitor T-20 publication-title: AIDS Res Human Retroviruses – volume: 19 start-page: 1919 year: 2005 end-page: 1922 ident: bib3 article-title: Inhibition of HIV-1 group M and O isolates by fusion inhibitors publication-title: AIDS – volume: 10 start-page: S75 year: 2005 ident: bib23 article-title: Impact of mutations in HR2 of HIV-1 env gp41 on susceptibility to Enfuvirtide publication-title: Antivir Ther – volume: 38 start-page: 1370 year: 2000 end-page: 1374 ident: bib19 article-title: Emergence of drug resistance mutations in HIV-2 infected subjects undergoing antiretroviral therapy publication-title: J Clin Microbiol – volume: 22 start-page: 357 year: 2006 end-page: 366 ident: bib8 article-title: Susceptibility to antiretroviral drugs of CRF01_AE, CRF02_AG, and subtype C viruses from untreated patients of Africa and Asia: comparative genotypic and phenotypic data publication-title: AIDS Res Hum Retroviruses – volume: 7 start-page: 17 year: 2002 ident: bib14 article-title: Impact of HIV-1 gp41 amino acid substitutions (positions 36–45) on susceptibility to T20 (Enfuvirtide) publication-title: Antivir Ther – volume: 33 start-page: 134 year: 2003 end-page: 139 ident: bib21 article-title: Uncommon mutations at residue positions critical for Enfuvirtide (T-20) resistance in Enfuvirtide-naive patients infected with B and non-B HIV-1 strains publication-title: J Acquir Immune Defic Syndr – volume: 7 start-page: 92 year: 2002 end-page: 96 ident: bib9 article-title: The impact of HIV-1 subtype on the clinical response on HAART publication-title: J HIV Ther – volume: 8 start-page: 98 year: 2006 end-page: 107 ident: bib11 article-title: Efficacy of antiretroviral therapy in individuals infected with HIV-1 non-B subtypes publication-title: AIDS Rev – volume: 20 start-page: 816 year: 2004 end-page: 818 ident: bib16 article-title: Non-B HIV-1 subtypes: replicative capacity and responses to antiretroviral therapy publication-title: AIDS Res Hum Retroviruses – volume: 41 start-page: 4313 year: 2002 end-page: 4316 ident: bib20 article-title: Rapid assessment of phenotypic resistance to protease inhibitors in HIV group O publication-title: J Clin Microbiol – volume: 18 start-page: 1787 year: 2004 end-page: 1794 ident: bib22 article-title: Characterization of determinants of genotypic and phenotypic resistance to Enfuvirtide in baseline and on-treatment HIV-1 isolates publication-title: AIDS – volume: 21 start-page: 583 year: 2005 end-page: 585 ident: bib17 article-title: Enfuvirtide is active against HIV-1 group O publication-title: AIDS Res Hum Retroviruses – volume: 7 start-page: 1610 year: 2003 end-page: 1613 ident: bib13 article-title: Baseline susceptibility of primary HIV-1 to entry inhibitors publication-title: J Virol – volume: 49 start-page: 1113 year: 2005 end-page: 1119 ident: bib24 article-title: Emergence and evolution of Enfuvirtide resistance following long-term therapy involves heptad repeat 2 mutations within gp41 publication-title: Antimicrob Agents Chemother – volume: 21 start-page: 430 year: 2005 end-page: 433 ident: bib1 article-title: Enfuvirtide binding domain is highly conserved in non-B HIV-1 strains from Cameroon, West Central Africa publication-title: AIDS Res Hum Retroviruses – volume: 10 start-page: S75 year: 2005 ident: 10.1016/j.jcv.2006.09.002_bib23 article-title: Impact of mutations in HR2 of HIV-1 env gp41 on susceptibility to Enfuvirtide publication-title: Antivir Ther – volume: 8 start-page: 98 year: 2006 ident: 10.1016/j.jcv.2006.09.002_bib11 article-title: Efficacy of antiretroviral therapy in individuals infected with HIV-1 non-B subtypes publication-title: AIDS Rev – volume: 7 start-page: 139 year: 2005 ident: 10.1016/j.jcv.2006.09.002_bib18 article-title: Enfuvirtide, the first fusion inhibitor to treat HIV infection publication-title: AIDS Rev – volume: 22 start-page: 357 year: 2006 ident: 10.1016/j.jcv.2006.09.002_bib8 article-title: Susceptibility to antiretroviral drugs of CRF01_AE, CRF02_AG, and subtype C viruses from untreated patients of Africa and Asia: comparative genotypic and phenotypic data publication-title: AIDS Res Hum Retroviruses doi: 10.1089/aid.2006.22.357 – volume: 7 start-page: 17 issue: Suppl. year: 2002 ident: 10.1016/j.jcv.2006.09.002_bib14 article-title: Impact of HIV-1 gp41 amino acid substitutions (positions 36–45) on susceptibility to T20 (Enfuvirtide) in vitro: analysis of primary isolates recovered from patients during chronic Enfuvirtide treatment and site-directed mutants in NL4-3 publication-title: Antivir Ther – volume: 38 start-page: 1370 year: 2000 ident: 10.1016/j.jcv.2006.09.002_bib19 article-title: Emergence of drug resistance mutations in HIV-2 infected subjects undergoing antiretroviral therapy publication-title: J Clin Microbiol doi: 10.1128/JCM.38.4.1370-1374.2000 – volume: 20 start-page: 477 year: 2004 ident: 10.1016/j.jcv.2006.09.002_bib5 article-title: Sensitivity of HIV-1 subtype C isolates to entry inhibitor T-20 publication-title: AIDS Res Human Retroviruses doi: 10.1089/088922204323087714 – volume: 28 start-page: 495 year: 1990 ident: 10.1016/j.jcv.2006.09.002_bib2 article-title: Rapid and simple method for purification of nucleic acids publication-title: J Clin Microbiol doi: 10.1128/JCM.28.3.495-503.1990 – volume: 7 start-page: 1610 year: 2003 ident: 10.1016/j.jcv.2006.09.002_bib13 article-title: Baseline susceptibility of primary HIV-1 to entry inhibitors publication-title: J Virol doi: 10.1128/JVI.77.2.1610-1613.2003 – volume: 79 start-page: 764 year: 2005 ident: 10.1016/j.jcv.2006.09.002_bib15 article-title: Mutations conferring resistance to HIV-1 fusion inhibitors are restricted by gp41 and rev-responsive element functions publication-title: J Virol doi: 10.1128/JVI.79.2.764-770.2005 – volume: 21 start-page: 430 year: 2005 ident: 10.1016/j.jcv.2006.09.002_bib1 article-title: Enfuvirtide binding domain is highly conserved in non-B HIV-1 strains from Cameroon, West Central Africa publication-title: AIDS Res Hum Retroviruses doi: 10.1089/aid.2005.21.430 – volume: 70 start-page: 777 year: 2001 ident: 10.1016/j.jcv.2006.09.002_bib6 article-title: Mechanisms of viral membrane fusion and its inhibition publication-title: Annu Rev Biochem doi: 10.1146/annurev.biochem.70.1.777 – volume: 40 start-page: 24 year: 2005 ident: 10.1016/j.jcv.2006.09.002_bib7 article-title: Distinct patterns of emergence and fading of K103N and Y181C in women with subtype A vs. D after single-dose nevirapine: HIVNET 012 publication-title: J Acquir Immune Defic Syndr doi: 10.1097/01.qai.0000174656.71276.d6 – volume: 20 start-page: 816 year: 2004 ident: 10.1016/j.jcv.2006.09.002_bib16 article-title: Non-B HIV-1 subtypes: replicative capacity and responses to antiretroviral therapy publication-title: AIDS Res Hum Retroviruses doi: 10.1089/0889222041725271 – volume: 7 start-page: 92 year: 2002 ident: 10.1016/j.jcv.2006.09.002_bib9 article-title: The impact of HIV-1 subtype on the clinical response on HAART publication-title: J HIV Ther – volume: 18 start-page: 1787 year: 2004 ident: 10.1016/j.jcv.2006.09.002_bib22 article-title: Characterization of determinants of genotypic and phenotypic resistance to Enfuvirtide in baseline and on-treatment HIV-1 isolates publication-title: AIDS doi: 10.1097/00002030-200409030-00007 – volume: 2 start-page: 325 year: 2005 ident: 10.1016/j.jcv.2006.09.002_bib12 article-title: Impact of HIV-1 subtype and antiretroviral therapy on protease and reverse transcriptase genotype: results of a global collaboration publication-title: PLoS Med doi: 10.1371/journal.pmed.0020112 – volume: 19 start-page: 1401 year: 2005 ident: 10.1016/j.jcv.2006.09.002_bib4 article-title: Effect of naturally-occurring gp41 HR1 variations on susceptibility of HIV-1 to fusion inhibitors publication-title: AIDS doi: 10.1097/01.aids.0000180785.25800.de – volume: 21 start-page: 583 year: 2005 ident: 10.1016/j.jcv.2006.09.002_bib17 article-title: Enfuvirtide is active against HIV-1 group O publication-title: AIDS Res Hum Retroviruses doi: 10.1089/aid.2005.21.583 – volume: 19 start-page: 1919 year: 2005 ident: 10.1016/j.jcv.2006.09.002_bib3 article-title: Inhibition of HIV-1 group M and O isolates by fusion inhibitors publication-title: AIDS doi: 10.1097/01.aids.0000188425.79914.e4 – volume: 78 start-page: 7582 year: 2004 ident: 10.1016/j.jcv.2006.09.002_bib10 article-title: Determinants of HIV-1 baseline susceptibility to the fusion inhibitors Enfuvirtide and T-649 reside outside the peptide interaction site publication-title: J Virol doi: 10.1128/JVI.78.14.7582-7589.2004 – volume: 33 start-page: 134 year: 2003 ident: 10.1016/j.jcv.2006.09.002_bib21 article-title: Uncommon mutations at residue positions critical for Enfuvirtide (T-20) resistance in Enfuvirtide-naive patients infected with B and non-B HIV-1 strains publication-title: J Acquir Immune Defic Syndr doi: 10.1097/00126334-200306010-00003 – volume: 49 start-page: 1113 year: 2005 ident: 10.1016/j.jcv.2006.09.002_bib24 article-title: Emergence and evolution of Enfuvirtide resistance following long-term therapy involves heptad repeat 2 mutations within gp41 publication-title: Antimicrob Agents Chemother doi: 10.1128/AAC.49.3.1113-1119.2005 – volume: 41 start-page: 4313 year: 2002 ident: 10.1016/j.jcv.2006.09.002_bib20 article-title: Rapid assessment of phenotypic resistance to protease inhibitors in HIV group O publication-title: J Clin Microbiol doi: 10.1128/JCM.40.11.4313-4316.2002 |
SSID | ssj0015347 |
Score | 1.908425 |
Snippet | Data on susceptibility of HIV-1 non-B subtypes to Enfuvirtide (ENF) is rather limited.
To determine if ENF could be active
in vitro against HIV-1 non-B... Abstract Background Data on susceptibility of HIV-1 non-B subtypes to Enfuvirtide (ENF) is rather limited. Objective To determine if ENF could be active in... Data on susceptibility of HIV-1 non-B subtypes to Enfuvirtide (ENF) is rather limited. To determine if ENF could be active in vitro against HIV-1 non-B... Background: Data on susceptibility of HIV-1 non-B subtypes to Enfuvirtide (ENF) is rather limited. Objective: To determine if ENF could be active in vitro... Data on susceptibility of HIV-1 non-B subtypes to Enfuvirtide (ENF) is rather limited.BACKGROUNDData on susceptibility of HIV-1 non-B subtypes to Enfuvirtide... |
SourceID | proquest pubmed pascalfrancis crossref elsevier |
SourceType | Aggregation Database Index Database Enrichment Source Publisher |
StartPage | 176 |
SubjectTerms | Adult Allergy and Immunology Amino Acid Sequence Biological and medical sciences Drug resistance Enfuvirtide Female Fundamental and applied biological sciences. Psychology Gp41 HIV Envelope Protein gp41 - genetics HIV Envelope Protein gp41 - immunology HIV Envelope Protein gp41 - pharmacology HIV Fusion Inhibitors - pharmacology HIV Infections - virology HIV-1 HIV-1 - drug effects HIV-1 - genetics HIV-1 - isolation & purification Human immunodeficiency virus 1 Human viral diseases Humans Infectious Disease Infectious diseases Male Medical sciences Microbiology Middle Aged Miscellaneous Peptide Fragments - pharmacology Phylogeny Subtypes Viral diseases Virology |
Title | Susceptibility of HIV-1 non-B subtypes and recombinant variants to Enfuvirtide |
URI | https://www.clinicalkey.com/#!/content/1-s2.0-S1386653206003209 https://www.clinicalkey.es/playcontent/1-s2.0-S1386653206003209 https://dx.doi.org/10.1016/j.jcv.2006.09.002 https://www.ncbi.nlm.nih.gov/pubmed/17196877 https://www.proquest.com/docview/20263450 https://www.proquest.com/docview/68920478 |
Volume | 38 |
hasFullText | 1 |
inHoldings | 1 |
isFullTextHit | |
isPrint | |
link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1La9wwEBYhpVAopenTabvVoaeCupIsWfIxDQmblO4lTclNyJYEG9LdpV4v5JLf3pFsbwjNA3LxwYweHs-MRtI3Mwh90eCwOa8pka6uiKhyT2whNJGKllymHPoxdvjntJiciuMzebaF9odYmAir7G1_Z9OTte7fjHtujpez2fiE5TFXW84prNnwjEF8Qqgo69-uNjAPUOhUZCwSk0g93GwmjNd5ve7vI8rNycota9PzpW2AY6ErdXG3L5rWpMOX6EXvTOK9br47aMvPX6GnXXnJy9doetI2CbWSALCXeBHw5Og3YRi2_OQ7btoqHsA22M4djhvjP1WCxeA17J8jPAavFvhgHtr1DAZw_g06PTz4tT8hff0EUkumVkTnVtq8jOlbqPaCVraoubBBwy7EOyaVKp0FUlrUOibqYkHowGotnHXeOZq_RdswIf8e4VBpW0le8xwcsNwzy7hyVDAaQogp1jNEB86Zuk8uHmtcXJgBRXZugNmx6GVhaGmA2Rn6ummy7DJr3EfMh99hhpBRMHIG7P59jdRtjXzTq2ljmGm4oeY_UcqQ2LS8IY0PDTi6ISnX3wU-gADhzNDnQXQMqHG8m7Fzv2gb6IUXuZD0bopClzymUsrQu07mrntXYEa1UruPm_UH9Kw7sI4YnY9oe_W39Z_A01pVo6RKI_Rk7-jHZPoPdG8klw |
linkProvider | Elsevier |
linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1Lb9QwELZKEaISQrxawqP1gROSWT9j5whVqy20e2mLerOc2Ja2gt0V2azUC7-dcR5bVbRF4pJDNGM7k_F4xv48g9AHAw6bD4YS5auSyFIE4nJpiNK04KrNoZ_uDp9M8vG5_HqhLjbQ_nAXJsEqe9vf2fTWWvdvRr00R4vpdHTKRMrVJjiFNRuexQP0UCqhE67v0-81zgNmdFtlLFGTRD4cbbYgr8tq1R9IFOutlVsWpycLV4PIYlfr4m5ntF2UDp-hp703iT93A36ONsLsBXrU1Ze8eokmp03dwlZaBOwVnkc8PvpOGIaYn3zBdVOmHdgau5nHKTL-Wba4GLyCADrhY_Byjg9msVlNoQMfXqHzw4Oz_THpCyiQSjG9JEY45USR8rdQEyQtXV5x6aKBMCR4prQuvANSmlcmZepiUZrIKiO988F7KrbRJgwovEY4lsaVildcgAcmAnOMa08lozHGlGM9Q3SQnK367OKpyMUPO8DILi0IO1W9zC0tLAg7Qx_XLIsutcZ9xHz4HXa4MwpWzoLhv49J38YU6n6e1pbZmltq_9KlDMk15w11_FeHuzc05fq7wAmQUuoM7Q2qY2Eep8MZNwvzpoZWeC6kondT5KbgKZdShnY6nbtuXYMdNVq_-b9R76HH47OTY3t8NPn2Fm11u9cJsPMObS5_NeE9uF3LcredVn8A-QcmKg |
openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Susceptibility+of+HIV-1+non-B+subtypes+and+recombinant+variants+to+Enfuvirtide&rft.jtitle=Journal+of+clinical+virology&rft.au=Holguin%2C+A&rft.au=Faudon%2C+J+L&rft.au=Labernardiere%2C+J+L&rft.au=Soriano%2C+V&rft.date=2007-02-01&rft.issn=1386-6532&rft.volume=38&rft.issue=2&rft.spage=176&rft.epage=180&rft_id=info:doi/10.1016%2Fj.jcv.2006.09.002&rft.externalDBID=NO_FULL_TEXT |
thumbnail_m | http://utb.summon.serialssolutions.com/2.0.0/image/custom?url=https%3A%2F%2Fcdn.clinicalkey.com%2Fck-thumbnails%2F13866532%2FS1386653207X01008%2Fcov150h.gif |